RESUMO
PURPOSE: Gestational diabetes mellitus (GDM) induces cardiovascular and metabolic disturbances in offspring. However, the effects of GDM in pain processing in offspring and whether male and female offspring are equally affected is not well known. Thus, we determined: i) whether GDM in mice affects offspring hindpaw mechanical sensitivity, capsaicin-induced spontaneous pain-like behaviors, and epidermal nerve fiber density (ENFD); and ii) whether there is sexual dimorphism in these parameters in offspring from GDM dams. METHODS: GDM was induced in pregnant ICR mice via i.p. streptozotocin (STZ). Then, glucose levels from dams and offspring were determined. Male and female offspring 2-3 months of age were evaluated for: a) baseline mechanical sensitivity of the hind paw by using von Frey filaments; b) number of flinches and time spent guarding induced by intraplantar capsaicin (0.1%); and c) density of PGP-9.5 and CGRP axons in the epidermis from the hind paw glabrous skin. RESULTS: Prepartum levels of glucose in STZ-treated dams were significantly increased compared to vehicle-treated dams; however, GDM or vehicle offspring displayed normal and similar blood glucose levels. Male and female GDM offspring showed significantly greater mechanical sensitivity and capsaicin-induced pain behaviors compared to vehicle offspring. Male GDM offspring displayed a slightly more intense nociceptive phenotype in the capsaicin test. PGP-9.5 and CGRP ENFD in hind paw glabrous skin were greater in male and female GDM offspring versus their controls. Sexual dimorphism was generally not observed in GDM offspring in most of the studied parameters. CONCLUSION: These results suggest GDM induced greater pain-like behaviors in adult offspring regardless of sex along with an increased ENFD of PGP-9.5 and CGRP in the hind paw glabrous skin. We show that GDM peripheral neuropathy differs from diabetic peripheral neuropathy acquired in adulthood and set the foundation to further study this in human babies exposed to GDM.
RESUMO
Recent in vitro studies have shown a role for the peptidyl-arginine deiminases (PADs) in bone resorption. However, it is unknown whether these enzymes are involved in bone loss in vivo. Thus, we evaluated the antiresorptive effect of a pan-PAD inhibitor in two murine models of osteoporosis: (a) primary osteoporosis induced by ovariectomy (OVX); and (b) secondary osteoporosis associated to Type-1 diabetes induced by streptozotocin (STZ, 50 mg/kg, i.p., five daily administrations). Five weeks after OVX and 15 weeks after injections of STZ, mice received daily administrations of Cl-amidine (3 or 10 mg/kg, i.p.) or vehicle for 30 consecutive days. At the end of the treatment, femur and vertebra were harvested for microCT analysis. Blood samples were collected for determination of antibodies against cyclic citrullinated peptides (anti-CCP) by enzyme-linked immunosorbent assay. Serum levels of anti-CCP antibodies from diabetic mice were not significantly different compared to control mice. However, a significant loss of both trabecular bone at the femoral neck and cortical bone at the femoral diaphysis was found in diabetic mice, and Cl-amidine did not reverse the diabetes-induced bone loss. Mice with OVX had significantly lower serum levels of anti-CCP compared to mice with sham surgery. OVX resulted in significant loss of both trabecular bone at the L5 vertebra and distal femoral metaphysis. Cl-amidine did not block the OVX-induced bone loss. Our results suggest that chronic treatment with Cl-amidine at the doses and period of time administered is not long enough to inhibit bone loss in two different murine models of osteoporosis.
Assuntos
Diabetes Mellitus Experimental/complicações , Ornitina/análogos & derivados , Osteoporose/tratamento farmacológico , Ovariectomia/efeitos adversos , Administração Oral , Animais , Modelos Animais de Doenças , Feminino , Fêmur/diagnóstico por imagem , Fêmur/efeitos dos fármacos , Camundongos , Ornitina/administração & dosagem , Ornitina/farmacologia , Osteoporose/diagnóstico por imagem , Osteoporose/etiologia , Coluna Vertebral/diagnóstico por imagem , Coluna Vertebral/efeitos dos fármacos , Estreptozocina , Resultado do Tratamento , Microtomografia por Raio-XRESUMO
Metformin is a widely used drug for the treatment of type 2 Diabetes Mellitus. Several studies have also suggested that metformin decreases blood pressure; although an interaction with α-adrenoceptors has been proposed, this mechanism needs to be further investigated. Since α1-adrenoceptors play a significant role to regulate vascular tone, this study has analysed the potential ability of metformin to block α1-adrenoceptors in rat aorta and tail artery. For this purpose, the contractile responses induced by noradrenaline, methoxamine, and phenylephrine were determined in the absence or presence of metformin in rat aorta and tail artery rings. In both arteries, noradrenaline, methoxamine, and phenylephrine produced concentration-dependent contractile responses. Interestingly, the contractile responses to noradrenaline, methoxamine, and phenylephrine were significantly and differentially blocked by metformin (1, 3.1 and/or 10â¯mM) but not by vehicle. These results suggest that metformin is capable to block α1-adrenoceptors and may explain, at least in part, the anti-hypertensive effect observed in several clinical trials.
Assuntos
Antagonistas de Receptores Adrenérgicos alfa 1/farmacologia , Aorta/efeitos dos fármacos , Aorta/fisiologia , Metformina/farmacologia , Receptores Adrenérgicos alfa 1/metabolismo , Cauda/irrigação sanguínea , Animais , Masculino , Metoxamina/farmacologia , Fenilefrina/farmacologia , Ratos , Ratos Wistar , Vasoconstrição/efeitos dos fármacosRESUMO
Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide belonging to the calcitonin gene peptide superfamily. CGRP is a potent vasodilator with potential therapeutic usefulness for treating vascular-related disease. This peptide is primarily located on C- and Aδ-fibers, which have extensive perivascular presence and a dual sensory-efferent function. Although CGRP has two major isoforms (α-CGRP and ß-CGRP), the α-CGRP is the isoform related to vascular actions. Release of CGRP from afferent perivascular nerve terminals has been shown to result in vasodilatation, an effect mediated by at least one receptor (the CGRP receptor). This receptor is an atypical G-protein coupled receptor (GPCR) composed of three functional proteins: (i) the calcitonin receptor-like receptor (CRLR; a seven-transmembrane protein), (ii) the activity-modifying protein type 1 (RAMP1), and (iii) a receptor component protein (RCP). Although under physiological conditions, CGRP seems not to play an important role in vascular tone regulation, this peptide has been strongly related as a key player in migraine and other vascular-related disorders (e.g., hypertension and preeclampsia). The present review aims at providing an overview on the role of sensory fibers and CGRP release on the modulation of vascular tone.
Assuntos
Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Acoplamento Neurovascular/fisiologia , Receptores de Peptídeo Relacionado com o Gene de Calcitonina/metabolismo , Doenças Vasculares/tratamento farmacológico , Doenças Vasculares/metabolismo , Vasodilatação/fisiologia , Medicina Baseada em Evidências , Humanos , Masculino , Terapia de Alvo Molecular/métodosRESUMO
Objetivo: con la evidencia más reciente, desarrollar una guía de práctica clínica para el manejo de dispepsia dirigida a pacientes, personal asistencial, administrativo y entes gubernamentales de cualquier servicio de atención en Colombia. Materiales y métodos: esta guía fue desarrollada por un equipo multidisciplinario con el apoyo de la Asociación Colombiana de Gastroenterología, el Grupo Cochrane ITS y el Instituto de Investigaciones Clínicas de la Universidad Nacional de Colombia. Se desarrollaron preguntas clínicas relevantes y se realizó la búsqueda de guías nacionales e internacionales en bases de datos especializadas. Las guías existentes fueron evaluadas en términos de calidad y aplicabilidad; una guía cumplió con el criterio de adaptación, por lo que se adaptaron 2 de sus preguntas. El Grupo Cochrane realizó la búsqueda sistemática de la literatura. Las tablas de evidencia y recomendaciones fueron realizadas con base en la metodología GRADE. Las recomendaciones de la guía fueron socializadas en una reunión de expertos con entes gubernamentales y pacientes. Resultados: se desarrolló una guía de práctica clínica basada en la evidencia para el manejo de pacientes con dispepsia en Colombia. Conclusiones: el tamizaje de pacientes asintomáticos en Colombia, de forma adecuada y con estándares de calidad, tiene el potencial de impactar la carga de cáncer de colon en el país.
Objective: To provide an evidence-based clinical practice guideline for the management of dyspepsia for patients, caregivers, administrative and government bodies at all levels of care in Colombia. Materials and Methods: This guide was developed by a multidisciplinary team with the support of the Colombian Association of Gastroenterology, Cochrane STI Group and Clinical Research Institute of the Universidad Nacional de Colombia. Relevant clinical questions were developed and the search for national and international guidelines in databases was performed. Existing guidelines were evaluated for quality and applicability. One guideline met the criteria for adaptation of two of its clinical questions. Systematic literature searches were conducted by the Cochrane STI Group. The tables of evidence and recommendations were made based on the GRADE methodology. The recommendations of the guide were socialized in a meeting of experts with government agencies and patients. Results: An evidence-based Clinical Practice Guidelines for the management of dyspepsia was developed for the Colombian context. Conclusions: The opportune management of dyspepsia would have an impact of the disease in Colombia.
Assuntos
Humanos , Adulto , Dispepsia/diagnóstico , Dispepsia/tratamento farmacológico , Gastroscopia , Abordagem GRADERESUMO
Progesterone and 17ß-estradiol induce vasorelaxation through non-genomic mechanisms in several isolated blood vessels; however, no study has systematically evaluated the mechanisms involved in the relaxation induced by 17ß-estradiol and progesterone in the canine basilar and internal carotid arteries that play a key role in cerebral circulation. Thus, relaxant effects of progesterone and 17ß-estradiol on KCl- and/or PGF2α-pre-contracted arterial rings were investigated in absence or presence of several antagonists/inhibitors/blockers; the effect on the contractile responses to CaCl2 was also determined. In both arteries progesterone (5.6-180 µM) and 17ß-estradiol (1.8-180 µM): (1) produced concentration-dependent relaxations of KCl- or PGF2α-pre-contracted arterial rings; (2) the relaxations were unaffected by actinomycin D (10 µM), cycloheximide (10 µM), SQ 22,536 (100 µM) or ODQ (30 µM), potassium channel blockers and ICI 182,780 (only for 17ß-estradiol). In the basilar artery the vasorelaxation induced by 17ß-estradiol was slightly blocked by tetraethylammonium (10mM) and glibenclamide (KATP; 10 µM). In both arteries, progesterone (10-100 µM), 17ß-estradiol (3.1-31 µM) and nifedipine (0.01-1 µM) produced a concentration-dependent blockade of the contraction to CaCl2 (10 µM-10mM). These results suggest that progesterone and 17ß-estradiol produced relaxation in the basilar and internal carotid arteries by blockade of L-type voltage dependent Ca(2+) channel but not by genomic mechanisms or production of cAMP/cGMP. Potassium channels did not play a role in the relaxation to progesterone in both arteries or in the effect of 17ß-estradiol in the internal carotid artery; meanwhile KATP channels play a minor role on the effect of 17ß-estradiol in the basilar artery.
Assuntos
Canais de Cálcio/metabolismo , Estradiol/administração & dosagem , Progesterona/administração & dosagem , Vasodilatação/efeitos dos fármacos , Animais , Artéria Basilar/efeitos dos fármacos , Artéria Basilar/fisiologia , Artéria Carótida Interna/efeitos dos fármacos , Artéria Carótida Interna/fisiologia , Humanos , Técnicas de Cultura de Órgãos , Canais de Potássio/metabolismo , Transdução de Sinais/efeitos dos fármacos , Vasodilatação/fisiologiaRESUMO
Testosterone induces vasorelaxation through non-genomic mechanisms in several isolated blood vessels, but no study has reported its effects on the canine basilar artery, an important artery implicated in cerebral vasospasm. Hence, this study has investigated the mechanisms involved in testosterone-induced relaxation of the canine basilar artery. For this purpose, the vasorelaxant effects of testosterone were evaluated in KCl- and/or PGF(2α)-precontracted arterial rings in vitro in the absence or presence of several antagonists/inhibitors/blockers; the effect of testosterone on the contractile responses to CaCl2 was also determined. Testosterone (10-180 µM) produced concentration-dependent relaxations of KCl- or PGF(2α)-precontracted arterial rings which were: (i) unaffected by flutamide (10 µM), DL-aminoglutethimide (10 µM), actinomycin D (10 µM), cycloheximide (10 µM), SQ 22,536 (100 µM) or ODQ (30 µM); and (ii) significantly attenuated by the blockers 4-aminopyridine (K(V); 1 mM), BaCl2 (K(IR); 30 µM), iberiotoxin (BK(Ca²+); 20 nM), but not by glybenclamide (K(ATP); 10 µM). In addition, testosterone (31, 56 and 180 µM) and nifedipine (0.01-1 µM) produced a concentration-dependent blockade of the contraction to CaCl2 (10 µM to 10 mM) in arterial rings depolarized by 60mM KCl. These results, taken together, show that testosterone relaxes the canine basilar artery mainly by blockade of voltage-dependent Ca²+ channels and, to a lesser extent, by activation of K+ channels (K(IR), K(V) and BK(Ca²+)). This effect does not involve genomic mechanisms, production of cAMP/cGMP or the conversion of testosterone to 17ß-estradiol.
Assuntos
Artéria Basilar/efeitos dos fármacos , Canais de Cálcio/metabolismo , Canais de Potássio/metabolismo , Testosterona/farmacologia , Vasodilatação , Vasodilatadores/farmacologia , 4-Aminopiridina/farmacologia , Adenina/análogos & derivados , Adenina/farmacologia , Aminoglutetimida/farmacologia , Antagonistas de Receptores de Andrógenos/farmacologia , Animais , Inibidores da Aromatase/farmacologia , Compostos de Bário/farmacologia , Artéria Basilar/fisiologia , Bloqueadores dos Canais de Cálcio/farmacologia , Cloretos/farmacologia , Cicloeximida/farmacologia , Dactinomicina/farmacologia , Cães , Inibidores Enzimáticos/farmacologia , Flutamida/farmacologia , Técnicas In Vitro , Masculino , Nifedipino/farmacologia , Inibidores da Síntese de Ácido Nucleico/farmacologia , Oxidiazóis/farmacologia , Bloqueadores dos Canais de Potássio/farmacologia , Inibidores da Síntese de Proteínas/farmacologia , Quinoxalinas/farmacologiaRESUMO
The importance of calcitonin gene-related peptide (CGRP) in the regulation of vascular tone has been widely documented. Indeed, stimulation of the perivascular sensory outflow in pithed rats results in vasodepressor responses, which are mediated by CGRP release. These vasodepressor responses are inhibited by clonidine via prejunctional alpha(2A/2C)-adrenoceptors, but no study has yet reported the role of prejunctional 5-hydroxytryptamine (5-HT) receptors in this experimental model. Since activation of prejunctional 5-HT(1) receptors results in inhibition of neurotransmitter release, this study sets out to investigate as an initial approach the role of 5-HT(1B) receptors in the inhibition of the vasodepressor sensory outflow in pithed rats. Male Wistar pithed rats were pretreated with hexamethonium (2mg/kg.min) followed by i.v. continuous infusions of methoxamine (20 microg/kg min), and then by saline (0.02 ml/min) or CP-93,129 (a rodent 5-HT(1B) receptor agonist; 0.1, 1 and 10 microg/kg min). Under these conditions, electrical stimulation (0.56-5.6 Hz; 50 V and 2 ms) of the spinal cord (T(9)-T(12)) resulted in frequency-dependent decreases in diastolic blood pressure. The infusions of CP-93,129, as compared to those of saline, inhibited the vasodepressor responses induced by electrical stimulation without affecting those to i.v. bolus injections of exogenous alpha-CGRP (0.1, 0.18, 0.31, 0.56 and 1 microg/kg). This inhibition by CP-93,129 was abolished by the antagonists GR127935 (5-HT(1B/1D)) or SB224289 (5-HT(1B)), but not by BRL15572 (5-HT(1D)). The above results suggest that CP-93,129-induced inhibition of the vasodepressor (perivascular) sensory outflow in pithed rats is mainly mediated by activation of prejunctional 5-HT(1B) receptors.
Assuntos
Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Agonistas do Receptor 5-HT1 de Serotonina , Vasoconstritores/uso terapêutico , Animais , Pressão Sanguínea/efeitos dos fármacos , Peptídeo Relacionado com Gene de Calcitonina/farmacologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Estimulação Elétrica , Frequência Cardíaca/efeitos dos fármacos , Hexametônio/farmacologia , Infusões Intravenosas , Masculino , Metoxamina/farmacologia , Piperidonas/farmacologia , Piridinas/farmacologia , Pirróis/farmacologia , Ratos , Ratos Wistar , Receptor 5-HT1B de Serotonina/metabolismo , Agonistas do Receptor de Serotonina/farmacologia , Cloreto de Sódio/farmacologia , Medula Espinal , Compostos de Espiro/farmacologia , Fatores de Tempo , Vasoconstritores/administração & dosagem , Vasoconstritores/farmacologiaRESUMO
This study analysed the inhibition produced by the agonists moxonidine (imidazoline I(1) receptors>alpha(2)-adrenoceptors) and agmatine (endogenous ligand of imidazoline I(1)/I(2) receptors), using B-HT 933 (6-ethyl-5,6,7,8-tetrahydro-4H-oxazolo[4,5-d]azepin-2-amine dihydrochloride; alpha(2)-adrenoceptors) for comparison, on the rat cardioaccelerator sympathetic outflow. Male Wistar rats were pithed and prepared to stimulate the cardiac sympathetic outflow or to receive i.v. bolus of exogenous noradrenaline. Sympathetic stimulation or noradrenaline produced, respectively, frequency-dependent and dose-dependent tachycardic responses. I.v. continuous infusions of moxonidine (3 and 10 microg/kg min), agmatine (1000 and 3000 microg/kg min) and B-HT 933 (30 and 100 microg/kg min) inhibited the tachycardic responses to sympathetic stimulation, but not those to noradrenaline. The cardiac sympatho-inhibition by either moxonidine (3 microg/kg min) or B-HT 933 (30 microg/kg min) was not modified by i.v. injections of saline or the antagonists AGN192403 [(+/-)-2-endo-Amino-3-exo-isopropylbicyclo[2.2.1]heptane hydrochloride; 3000microg/kg; imidazoline I(1) receptors] or BU224 (2-(4,5-dihydroimidazol-2-yl)quinoline hydrochloride; 300 microg/kg; imidazoline I(2) receptors) and abolished by rauwolscine (300 microg/kg; alpha(2)-adrenoceptors). At the same doses of these compounds, the sympatho-inhibition to moxonidine (10 microg/kg min) and agmatine (1000 microg/kg min) was: (1) not modified by saline, AGN192403 or BU224; (2) partially blocked by rauwolscine or the combination of rauwolscine plus BU224; and (3) abolished by the combination of rauwolscine plus AGN192403. These results demonstrate that the cardiac sympatho-inhibition to: (1) 3 microg/kg min moxonidine or 30 microg/kg min B-HT 933 involves alpha(2)-adrenoceptors; and (2) 10 microg/kg min moxonidine or 1000 microg/kg min agmatine involves alpha(2)-adrenoceptors and imidazoline I(1) receptors.
Assuntos
Agmatina/farmacologia , Encéfalo/cirurgia , Frequência Cardíaca/efeitos dos fármacos , Imidazóis/farmacologia , Sistema Nervoso Simpático/efeitos dos fármacos , Sistema Nervoso Simpático/fisiologia , Agonistas de Receptores Adrenérgicos alfa 2 , Animais , Azepinas/farmacologia , Compostos Bicíclicos com Pontes/administração & dosagem , Compostos Bicíclicos com Pontes/farmacologia , Estimulação Elétrica , Heptanos/administração & dosagem , Heptanos/farmacologia , Imidazóis/administração & dosagem , Infusões Intravenosas , Masculino , Norepinefrina/administração & dosagem , Norepinefrina/farmacologia , Ratos , Ratos Wistar , Cloreto de Sódio/administração & dosagem , Cloreto de Sódio/farmacologia , Especificidade por Substrato , Sistema Nervoso Simpático/fisiopatologia , Taquicardia/fisiopatologia , Fatores de Tempo , Ioimbina/administração & dosagem , Ioimbina/farmacologiaRESUMO
OBJETIVO. Comparar la eficacia, seguridad y adherencia del manitol y polietilenglicol para la preparación intestinal de colonoscopias diagnósticas.ESTUDIO. Clínico Controlado Aleatorizado Doble Ciego.SET. Unidad de Gastroenterología Hospital Central de la Policía.PARTICIPANTES. 297 sujetos fueron incluidos, 142 al grupo A (polietilenglicol) y 155 al grupo B (Manitol). INTERVENCIÓN. Preparación con 4 litros de solución de Polietilenglicol en el grupo A, preparación con 500 ml de Manitol al 20 por ciento más Bisacodilo 20 mgs en el Grupo B.PRINCIPALES RESULTADOS MEDIDOS. Evaluación cualitativa y cuantitativa de la calidad de preparación en colon proximal y distal según la escala de Vanner, proporción de colonoscopia total, incidencia de eventos adversos, proporción de sujetos que completaron los protocolos, efecto sobre los niveles séricos de sodio, potasio, cloro y calcio.RESULTADOS. Los grupos fueron comparables en edad y sexo (p > 0,05), todos los sujetos admitidos fueron incluidos en el análisis: No se encontró diferencia en los grupos al evaluar proporción de colonoscopia completa (A) 92,9 por ciento, (B) 90 por ciento, (IC 95 por ciento 0,96-1,09); preparación excelente o buena (A) 86,6 por ciento, (B) 91,6 por ciento (IC 95 por ciento 0,87-1,02); frecuencia de eventos adversos no serios (A) 20,5 por ciento, (B) 23,9 por ciento (IC 95 por ciento 0,56-1,31); no se encontró diferencia sobre electrolitos séricos.CONCLUSIONES. La preparación intestinal para colonoscopia diagnóstica con manitol o polietilenglicol proporcionan resultados de limpieza colónica semejante, siendo medicamentos seguros, confiables y bien tolerados, el manitol, con un costo significativamente menor que el de polietilenglicol, lo constituye en la alternativa de primera elección para colonoscopia diagnóstica
Assuntos
Masculino , Humanos , Colonoscopia , Método Duplo-Cego , ManitolRESUMO
INTRODUCTION: Schizophrenic patients show sleep abnormalities, consisting mainly of decreased delta sleep time, short rapid eye movement (REM) sleep latency, and a reduction in sleep continuity variables. Olanzapine is a novel antipsychotic drug with an atypical profile. The goals of the present study were to determine if pre-treatment sleep variables and the initial response to olanzapine administration on the sleep variables can predict the clinical improvement after eight weeks of treatment. MATERIAL AND METHODS: Twenty-one schizophrenic (DSM-IV) patients were studied. They were clinically evaluated using the positive and negative syndrome scale (PANSS), and the Calgary Depression Scale for Schizophrenia. Sleep recordings were as follows: one acclimatization nigh, one night of baseline recordings, and two nights in which the patients receives olanzapine 10 mg, one hour before bedtime. For sleep-comparison purposes, a group of normal volunteers were also studied with acclimatization and baseline nights. After the sleep recordings ended patients continued with the administration of 10 mg/d of olanzapine, that was titrated as needed up to 20 mg/d or down to 5 mg/d. Evaluations were conducted weekly. RESULTS: Awakening and sleep latency variables were significantly higher in schizophrenic patients compared to normal volunteers. Delta sleep was lower in patients than in normal subjects, with no detectable values in some of the schizophrenics. There was not correlation at baseline, between psychopathological scores and delta sleep or other sleep variables. The acute administration of olanzapine 10 mg produced an improvement in continuity sleep variables as well as increase in deltas sleep percentage. Having less than 10% of delta sleep at baseline predicted a good clinical outcome. Eleven of 18 patients showed good clinical improvement after eight weeks of treatment with olanzapine, those were the subjects that had an augmentation of delta sleep above 10% with the first two doses of olanzapine, with minimal side effects. CONCLUSIONS: To have low delta sleep at baseline and the effect of the augmentation of this variable in schizophrenic patients seems to predict a good response to olanzapine. Olanzapine was therapeutically useful, well-tolerated medication, with a favorable safety profile.
Assuntos
Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Esquizofrenia/tratamento farmacológico , Esquizofrenia/fisiopatologia , Fases do Sono , Adulto , Feminino , Humanos , Masculino , OlanzapinaRESUMO
La enfermedad de Menetrier forma parte del grupo de las gastropatias hiperplasicas de tipo foveolar, cuya etiologia no se ha establecido claramente. Presentamos el caso de un paciente con criterios clinicos, paraclinicos e histologicos de enfermedad de Menetrier quien presento mejoria de todos los parametros despues del tratamiento de erradicacion de Heli-cobacter pylori, lo cual sugiere que podra tambien ser parte del espectro de alteraciones gastricas por esa bacteria
Assuntos
Humanos , Masculino , Adulto , Gastrite Hipertrófica/etiologia , Infecções por Helicobacter , Helicobacter pyloriRESUMO
Las características principales de una sutura ideal es que sea fuerte, fácilmente manipulable, nudo seguro, mínima reactividad tisular, que no favorezca infecciones y que no sea costosa. Los materiales de sutura son clasificados y se propone el buen uso de ellos en la cirugía dermatológica para obtener los mejores resultados
Assuntos
Humanos , Equipamentos Cirúrgicos/normas , Suturas/normas , Categute/normas , Agulhas/normasRESUMO
Diversas enfermedades cutáneas se caracterizan por alteraciones localizadas preferentemente en la zona de membrana basal. Estas dermatosis se han hereditarias y adquiridas. Se pueden encontrar cambios ultraestructurales en la membrana basal, muchos de los cuales serían causados por fenómenos autoinmunes. Múltiples investigaciones han permitido aclarar la morfogénesis de las lesiones clínicamente visibles que afectan esta zona en particular. En la presente revisión se realiza una puesta al día de la última información de la literatura sobre estas interesantes enfermedades
Assuntos
Humanos , Membrana Basal/ultraestrutura , Dermatopatias/patologia , Dermatite Herpetiforme/patologia , Epidermólise Bolhosa Adquirida/patologia , Epidermólise Bolhosa Juncional/patologia , Epidermólise Bolhosa Distrófica/patologia , Epidermólise Bolhosa Simples/patologia , Lúpus Eritematoso Discoide/patologia , Penfigoide Mucomembranoso Benigno/patologia , Penfigoide Bolhoso/patologiaRESUMO
Las enfermedades hepatobiliares se asocian con frecuencia a alteraciones de la piel y anexos. Los cambios cutáneos no son específicos y los más comunes son prurito, ictericia, hiperpigmentación, telangectasias, cambios endocrinos y en los anexos. No hay clara correlación entre los cambios cutáneos y la severidad de la disfunción hepática. Las asociaciones entre piel e hígado son: 1) Manifestaciones cutáneas relacionadas con enfermedades hepatobiliares. 2) Alteraciones cutáneas y disfunción hepática asociada a una enfermedad sistémica